Prospective biomarker–treatment (Mamdouh et al., 2025)inkages (e.g., “F691L → switch to type-I TKI”) and companion-diagnostic plans de-risk label expansion, as demonstrated in FLT3-mutant AML trials (Perl, 2025). The gene discussed is FLT3; the disease is acute myeloid leukemia.